Suppr超能文献

选择性5-羟色胺再摄取抑制剂:优点、缺点及差异

The SSRIs: advantages, disadvantages and differences.

作者信息

Lane R, Baldwin D, Preskorn S

机构信息

International Pharmaceuticals, Pfizer Inc, 235 East 42nd St, New York, NY 10017, USA.

出版信息

J Psychopharmacol. 1995 Jan;9(2 Suppl):163-78. doi: 10.1177/0269881195009002011.

Abstract

The highly specific mechanism of action of the selective serotonin re-uptake inhibitors (SSRIs) confers advantages on this group, relative to other classes of antidepressant, and thus represents a significant advance in the pharmacotherapy of depression. Whilst their clinical efficacy is equivalent to that of the tricyclic antidepressants (TCAs), the SSRIs have a greatly reduced risk of toxicity in overdose and have been shown to be significantly better tolerated. Specifically, the SSRIs have a low incidence of anticholinergic effects and are essentially devoid of cardiotoxicity. This tolerability advantage may be of significance in improving compliance and hence cost-effectiveness of treatment, particularly in the long term. Despite a lack of sedative effect, there is evidence that SSRIs are more effective than TCAs in the treatment of depression with anxiety. In addition, the SSRIs have been shown to be effective in obsessive-compulsive disorder, panic disorder and social phobia. Although superior efficacy has not been demonstrated for any one of the SSRIs, the structural diversity of this group is reflected in emerging qualitative and quantitative differences in side effects and drug interaction potential. Many of these differential features reflect important variations in pharmacological and pharmacokinetic profiles, including dosage flexibility, washout times, dose-plasma level proportionality and age-related changes in plasma levels. Fluoxetine, for example, has a considerably longer half-life than other SSRIs and side effects and drug interactions may thus occur for an extended period following discontinuation of treatment. Significant differences in the potential for drug interactions in this group are related to their relative potency for inhibition of important liver drug-metabolising enzymes including CYPIID6, CYPIA2 and CYPIIIA4. Large comparative clinical trials of the different SSRIs have yet to be undertaken; however, the differences that have already become apparent provide important information enabling the physician to choose an SSRI appropriate to the individual patient.

摘要

与其他类别的抗抑郁药相比,选择性5-羟色胺再摄取抑制剂(SSRI)高度特异的作用机制赋予了该类药物优势,因此代表了抑郁症药物治疗的一项重大进展。虽然其临床疗效与三环类抗抑郁药(TCA)相当,但SSRI过量时的毒性风险大大降低,且已证明耐受性明显更好。具体而言,SSRI的抗胆碱能效应发生率低,基本无心脏毒性。这种耐受性优势对于提高依从性进而改善治疗的成本效益可能具有重要意义,尤其是从长期来看。尽管没有镇静作用,但有证据表明SSRI在治疗伴有焦虑的抑郁症方面比TCA更有效。此外,SSRI已被证明对强迫症、惊恐障碍和社交恐惧症有效。虽然尚未证明任何一种SSRI具有卓越疗效,但该类药物结构的多样性体现在副作用和药物相互作用潜力方面新出现的质和量的差异上。这些差异特征许多反映了药理学和药代动力学特征的重要变化,包括剂量灵活性、洗脱时间、剂量-血浆水平比例以及血浆水平的年龄相关变化。例如,氟西汀的半衰期比其他SSRI长得多,因此在停药后较长一段时间内可能会出现副作用和药物相互作用。该类药物在药物相互作用潜力方面的显著差异与其对包括CYPIID6、CYPIA2和CYPIIIA4在内的重要肝脏药物代谢酶的抑制相对效力有关。尚未对不同的SSRI进行大规模的比较临床试验;然而,已经显现出的差异提供了重要信息,使医生能够为个体患者选择合适的SSRI。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验